(UroToday.com) Standard or high dose chemotherapy has curative potential in relapsed patients with germ cell tumor but is associated with significant toxicity. Although cisplatin-based induction chemotherapy is effective in treating metastatic testicular cancer, approximately 30% of patients will require salvage chemotherapy or surgery. Patients with platinum-refractory disease who can potentially be cured with salvage retroperitoneal lymph node dissection (RPLND) are difficult to identify. Additionally, metastatic testis cancer is potentially curable if localized to the retroperitoneum after failure of chemotherapy. At the 2020 Society of Urologic Oncology (SUO) Annual Virtual Meeting’s best of the testicular and penile cancer session, Dr. Sean Kern and colleagues presented their work describing the clinical characteristics and outcomes in patients with salvage RPLND for relapsed or refractory disease after induction or salvage chemotherapy in an effort to better identify patients who may be cured with surgery (those who do not need subsequent chemotherapy after RPLND).